Health Economics›Non-small cell lung cancer›Advanced or metastatic disease ROS1 inhibitor-naive

Advanced or metastatic disease ROS1 inhibitor-naive

Non-small cell lung cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Entrectinib monotherapy Variant #01	ROS1	R 671 143	28d	—	—	~2	~R 1 342 286 indirect	—
Crizotinib monotherapy Variant #01	ROS1	R 50 221	28d	11.1 mo	—	2	R 100 441 PFS proxy	12
Ceritinib monotherapy Variant #01	ROS1	R 35 198	28d	11.0 mo	—	2	R 70 395 PFS proxy	2
Repotrectinib monotherapy Variant #01 Partial	ROS1	—	28d	—	—	~2	—	—

4 of 4 regimens shown